|
Feb 27
|
GENFIT Announces Revenues and Cash Position as of December 31, 2024
|
|
Feb 21
|
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
|
|
Oct 10
|
High Growth Tech Stocks in France to Watch October 2024
|
|
Oct 9
|
Exclusive Networks And 2 High Growth Tech Stocks In France
|
|
Sep 24
|
Esker And Two High Growth Tech Stocks In France
|
|
Sep 23
|
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
|
|
Jul 26
|
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
|
|
Jun 17
|
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
|
|
Feb 29
|
GENFIT Announces Revenues and Cash Position as of December 31, 2023
|
|
Jan 15
|
GENFIT Announces 2024 Financial Calendar
|
|
Jan 11
|
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
|
|
Dec 8
|
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
|
|
Dec 7
|
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
|
|
Dec 6
|
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
|
|
Nov 9
|
GENFIT Reports Third Quarter 2023 Financial Information
|
|
Sep 20
|
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
|
|
Sep 5
|
GENFIT to Participate in Upcoming Investor Conferences
|